[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].
Tetsuzo
T
Tauchi
D000818:Animals; D001549:Benzamides; D002869:Chromosome Aberrations; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000502:physiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013873:Thionucleotides / Q000627:therapeutic use; D003986:Dibenzocycloheptenes
D001549:Benzamides; D016044:Fusion Proteins, bcr-abl; D000068877:Imatinib Mesylate; D010879:Piperazines; D010880:Piperidines; D011725:Pyridines; D011743:Pyrimidines; D015363:Quinolones; D013873:Thionucleotides; C408162:oblimersen; C115354:lonafarnib; D003986:Dibenzocycloheptenes; C402769:tipifarnib